Home / Health / Obesity Drugs: No Magic Bullet Found
Obesity Drugs: No Magic Bullet Found
9 Jul
Summary
- No single weight-loss drug excels in all health aspects.
- Tirzepatide causes significant muscle loss with weight loss.
- Subcutaneous semaglutide offers heart and kidney benefits.
A large-scale meta-analysis comparing 19 obesity drugs has determined that no single medication offers a complete solution. The study, involving nearly 100,000 patients, evaluated drugs based on weight loss, survival rates, cardiovascular health, kidney function, side effects, and quality of life.
Tirzepatide was found to be the most effective for weight loss, shedding nearly 15% of body weight in one year. However, it also resulted in the greatest loss of lean muscle mass. Drugs that promote substantial weight reduction are also associated with higher rates of nausea, vomiting, diarrhea, and patient discontinuation, with about half of patients stopping treatment within a year.
In terms of critical health outcomes, subcutaneous semaglutide emerged as the sole drug with high-certainty evidence of reducing all-cause mortality by approximately 19% and myocardial infarction by 28%. It also demonstrated efficacy in slowing kidney disease progression. Tirzepatide and semaglutide both showed benefits in reducing the risk of heart failure.
Despite significant weight reduction, no drug demonstrated a meaningful improvement in patient quality of life after one year, contrary to some clinical observations. In India, prescribing decisions are based on BMI thresholds, with cost also playing a role, leading to the wider availability of generic semaglutide.
